Background And Objectives: The prevalence of osteoporosis among patients with rheumatoid arthritis (RA) in the Duhok governorate of Iraqi Kurdistan underscores a significant health concern that intersects autoimmune and bone health. The present study aimed to assess the prevalence of osteoporosis among patients with rheumatoid arthritis (RA) in the Duhok governorate.
Methods: Detailed questionnaire to collect demographic data, essential for identifying factors influencing BMD, such as age, sex, and lifestyle were used. Participants then underwent Dual-energy X-ray Absorptiometry (DXA) scans, a precise imaging technique for measuring BMD.
Results: The study involved middle-aged adults with an average age of 57.6 years, primarily females (91.5%), who had rheumatoid arthritis (RA) for about 15 years. Most participants were non-educated (71.5%) and lived in urban areas (77.1%). The majority worked in moderately heavy jobs (58.6%) and were married (98.5%). Most patients did not engage in exercise (84.3%), were non-smokers (77.1%), and alcohol-free (100%). Nearly half had a family history of RA, and all were tuberculosis-free. Clinically, most patients were obese, with 65.7% having comorbidities like hypertension and diabetes. A significant proportion tested positive for rheumatoid factors (74.3% for Rheumatoid factor and 84.3% for Anti-CCP) but were negative for DAS28-ESR. None had subcutaneous nodules, erosions, or joint surgeries. Regarding treatment, 65.7% used one DMARD, while 34.3% used two, and only 5.7% were on biologics; 80% also used corticosteroids. Osteoporosis was prevalent, with 80% showing signs (34.2% with osteopenia and 45.8% with osteoporosis).
Conclusion: Such efforts should focus on integrating routine bone health evaluations into RA care protocols, necessitating collaborative endeavors among rheumatologists, endocrinologists, and primary care professionals. This interdisciplinary model aims not only at early diagnosis but also at formulating comprehensive management plans tailored to the unique needs of this demographic within Iraqi Kurdistan's healthcare framework.
Download full-text PDF |
Source |
---|
Int Immunopharmacol
December 2024
Department of Orthopaedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 250012, PR China. Electronic address:
Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to joint deformity and ultimately disability. The metabolite of quercetin, 4-Methylcatechol (4-MC), has been acknowledged for its anti-inflammatory and antioxidant properties; however, the protective effects of 4-MC on RA and its underlying mechanisms remain incompletely elucidated. In a collagen-induced arthritis (CIA) model, we observed that 4-MC effectively mitigated joint inflammation and bone destruction in CIA mice.
View Article and Find Full Text PDFClin Rheumatol
December 2024
Department of Medicine, University of Otago, Wellington, New Zealand.
Climate change and pollution are a major existential threat. Healthcare contributes a noteworthy 4-6% to the total carbon footprint and 5-7% of the total greenhouse gas (GHG) emissions. Environmental pollution and modern lifestyles are also contributing to the increased prevalence of autoimmune and lifestyle-related rheumatic disease.
View Article and Find Full Text PDFInflammopharmacology
December 2024
Department of Zoology, Government College University, Faisalabad, 38000, Pakistan.
Berberine (BBR), an alkaloid derivative mostly found in Oregon grapes and barberry shoots, has several medical properties, including anti-microbial, anti-tumorigenic, and anti-inflammatory properties. As such, it is a superior alternative to presently recommended medications. From previous researches, which showed that BBR has anti-arthritic qualities by blocking a number of inflammatory signalling pathways.
View Article and Find Full Text PDFIndian Heart J
December 2024
Jacobi Medical Center/North Central Bronx, Albert Einstein College of Medicine, NYC Health and Hospitals, 3424 Kossuth Avenue, Bronx, New York, 10467.
Aim: The present study aims to investigate the outcomes of Percutaneous coronary intervention (PCI) in patients with Rheumatoid arthritis (RA).
Methods: A systemic search was conducted from electronic databases (PubMed/Medline, Cochrane Library, and Google Scholar) from inception to 15 September 2023. All statistical analyses were conducted using Review Manager 5.
Arthritis Res Ther
December 2024
Memorial Herman Northwest Hospital, Houston, TX, 77089, USA.
Objectives: To assess immunogenicity and safety in patients with active rheumatoid arthritis (RA) transitioning from rituximab [US-licensed rituximab: Reference Product (RP); EU-approved rituximab: Reference Medicinal Product (RMP)] to DRL_RI (proposed rituximab biosimilar), in comparison to those continuing on RP/RMP.
Methods: This double-blind, randomized, Phase 3 study included 140 RA patients having prior exposure to RP/RMP; transitioned to DRL_RI (n = 70) or continued with RP/RMP (n = 70) for two 1000 mg infusions on Days 1 and 15. Assessments included Time-matched Rituximab Concentration (TMRC), anti-drug antibodies (ADAs), neutralizing antibodies (NAbs) and ADA titre over 12 weeks, and safety follow-up till 26 weeks.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!